US 4254056A
· Konno et al.
· 1981
[cited by applicant]
US 4573966A
· Weikl et al.
· 1986
[cited by applicant]
US 4653438A
· Russell
· 1987
[cited by applicant]
US 5045061A
· Seifert et al.
· 1991
[cited by applicant]
US 5263931A
· Miller
· 1993
[cited by applicant]
US 5314443A
· Rudnick
· 1994
[cited by applicant]
US 5315992A
· Dalton
· 1994
[cited by applicant]
US 5380284A
· Don
· 1995
[cited by applicant]
US 5419763A
· Hildebrand
· 1995
[cited by applicant]
US 5423755A
· Kesten et al.
· 1995
[cited by applicant]
US 5460610A
· Don
· 1995
[cited by applicant]
US 5599307A
· Bacher et al.
· 1997
[cited by applicant]
US 5681281A
· Vigil et al.
· 1997
[cited by applicant]
US 5720735A
· Dorros
· 1998
[cited by applicant]
US 6048332A
· Duffy et al.
· 2000
[cited by applicant]
US 6062223A
· Palazzo et al.
· 2000
[cited by applicant]
US 6135981A
· Dyke
· 2000
[cited by applicant]
US 6148222A
· Ramsey
· 2000
[cited by applicant]
US 6258087B1
· Edwards et al.
· 2001
[cited by applicant]
US 6623452B2
· Chien et al.
· 2003
[cited by applicant]
US 6685672B1
· Forman
· 2004
[cited by applicant]
US 7617005B2
· Demarais et al.
· 2009
[cited by applicant]
US 7653438B2
· Deem et al.
· 2010
[cited by applicant]
US 7717948B2
· Demarais et al.
· 2010
[cited by applicant]
US 8052668B2
· Sih
· 2011
[cited by applicant]
US 8372054B2
· Duffy et al.
· 2013
[cited by applicant]
US 8740849B1
· Fischell
· 2014
[cited by examiner]
US 8774913B2
· Demarais et al.
· 2014
[cited by applicant]
US 8840601B2
· Salahieh et al.
· 2014
[cited by applicant]
US 9114123B2
· Vafai et al.
· 2015
[cited by applicant]
US 20020014238A1
· Kotmel
· 2002
[cited by applicant]
US 20020177846A1
· Mulier
· 2002
[cited by applicant]
US 20030066532A1
· Gobel
· 2003
[cited by applicant]
US 20050288639A1
· Hibner
· 2005
[cited by applicant]
US 20090192505A1
· Askew et al.
· 2009
[cited by applicant]
US 20100087781A1
· Adams et al.
· 2010
[cited by applicant]
US 20120116438A1
· Salahieh et al.
· 2012
[cited by applicant]
US 20120209251A1
· Bates
· 2012
[cited by applicant]
US 20120215212A1
· Selzer et al.
· 2012
[cited by applicant]
US 20120259269A1
· Meyer
· 2012
[cited by applicant]
US 20130138082A1
· Salahieh
· 2013
[cited by examiner]
US 20150272666A1
· Wang
· 2015
[cited by applicant]
US 20200086093A1
· Wang
· 2020
[cited by applicant]
US 20210275784A1
· Wang
· 2021
[cited by applicant]
US 20210275785A1
· Wang
· 2021
[cited by applicant]
US 20210275786A1
· Wang
· 2021
[cited by applicant]
US 20210275787A1
· Wang
· 2021
[cited by applicant]
US 20220233827A1
· Wang et al.
· 2022
[cited by applicant]
US 20240277977A1
· Wang et al.
· 2024
[cited by applicant]
CN 1593359A
· 2005
[cited by applicant]
CN 101035593
· 2007
[cited by applicant]
CN 101861184A
· 2010
[cited by applicant]
CN 102481428A
· 2012
[cited by applicant]
CN 102573466
· 2012
[cited by applicant]
CN 102600546A
· 2012
[cited by applicant]
CN 102698354A
· 2012
[cited by applicant]
CN 102727986A
· 2012
[cited by applicant]
CN 102743163A
· 2012
[cited by applicant]
CN 107106820A
· 2017
[cited by applicant]
CN 110772311A
· 2020
[cited by applicant]
CN 113040895
· 2021
[cited by applicant]
CN 118555975
· 2024
[cited by applicant]
EP 2497524A1
· 2012
[cited by applicant]
EP 2914326
· 2023
[cited by applicant]
JP S5769814
· 1982
[cited by applicant]
JP H04215767A
· 1992
[cited by applicant]
JP H07308382A
· 1995
[cited by applicant]
JP 08508917A
· 1996
[cited by applicant]
JP 2000279524
· 2000
[cited by applicant]
JP 2004035128
· 2004
[cited by applicant]
JP 2004180892A
· 2004
[cited by applicant]
JP 2004528924A
· 2004
[cited by applicant]
JP 2005506101A
· 2005
[cited by applicant]
JP 2006502801A
· 2006
[cited by applicant]
JP 2010078379A
· 2010
[cited by applicant]
JP 2010519005A
· 2010
[cited by applicant]
JP 2010528815A
· 2010
[cited by applicant]
JP 2011519699A
· 2011
[cited by applicant]
JP 2012505050A
· 2012
[cited by applicant]
JP 2012508067A
· 2012
[cited by applicant]
JP 2012517858A
· 2012
[cited by applicant]
JP 2012524808A
· 2012
[cited by applicant]
JP 2013517847A
· 2013
[cited by applicant]
JP 2014524342A
· 2014
[cited by applicant]
JP 2014527272A
· 2014
[cited by applicant]
JP 2015536945
· 2015
[cited by applicant]
JP 2017533036A
· 2017
[cited by applicant]
JP 6389185B2
· 2018
[cited by applicant]
JP 2018153239
· 2018
[cited by applicant]
JP 2020189858
· 2020
[cited by applicant]
JP 2021046397
· 2021
[cited by applicant]
JP 2023027052
· 2023
[cited by applicant]
WO WO9421320A1
· 1994
[cited by applicant]
WO WO9618427A1
· 1996
[cited by applicant]
WO WO9717099A1
· 1997
[cited by applicant]
WO WO0119445A1
· 2001
[cited by applicant]
WO WO02051490A1
· 2002
[cited by applicant]
WO WO2006055695A1
· 2006
[cited by applicant]
WO WO2008106357A1
· 2008
[cited by applicant]
WO WO2009076732A1
· 2009
[cited by applicant]
WO WO2009082433A2
· 2009
[cited by applicant]
WO WO2010033686A1
· 2010
[cited by applicant]
WO WO2010124120A1
· 2010
[cited by applicant]
WO WO2011094367A1
· 2011
[cited by applicant]
WO WO2011119159A1
· 2011
[cited by applicant]
WO WO2013026565A1
· 2013
[cited by applicant]
WO WO2013028781A1
· 2013
[cited by applicant]
WO 2013067382
· 2013
[cited by applicant]
WO WO2013090848A1
· 2013
[cited by applicant]
WO WO2014070820A2
· 2014
[cited by applicant]
WO 2015058296
· 2015
[cited by applicant]
WO WO2016070032A1
· 2016
[cited by applicant]
WO 2023091475
· 2023
[cited by applicant]
Results of related clinical study described in Declaration under 37 C.F.R. section 1.132 filed in U.S. Appl. No. 16/986,717. This application is a continuation in part (CIP) of U.S. Appl. No. 16/986,717. (Year: 2024).
[cited by examiner]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Jan. 28, 2022”, 10 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 4 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed May 20, 2022”, w / English translation, 16 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 10 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-134047, Examiners Decision of Final Refusal mailed Jun. 21, 2022”, w / English translation, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 5, 22 to Non Final Office Action mailed Apr. 5, 2022”, 19 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 13, 23 to Final Office Action mailed May 15, 2023”, 19 pgs.
[cited by applicant]
“European Application Serial No. 23183741.0, Extended European Search Report mailed Jul. 21, 2023”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Advisory Action mailed Jul. 26, 2023”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Aug. 9, 2023 to Non Final Office Action mailed May 31, 2023”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Aug. 24, 2023”, 23 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,765, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,795, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,823, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Refusal mailed Jul. 6, 2021”, w English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Aug. 17, 2021”, w English Translation, 17 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-134047, Notification of Reasons for Refusal mailed Sep. 28, 2021”, w English Translation, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed Sep. 30, 2021”, 13 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Oct. 23, 20 to Office Action mailed Jun. 23, 2020”, w English Claims, 14 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Response filed Oct. 27, 2020 to Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 14 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Nov. 24, 2020 to Office Action mailed Jul. 2, 2020”, w English Claims, 16 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Response field Dec. 21, 2022 to Office Action mailed Nov. 22, 2022”, w English Translation, 11 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Preliminary Examination Report mailed Jan. 24, 2023”, w English Translation, 2 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Aug. 10, 2022 to Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 52 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowance mailed Feb. 3, 2023”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Feb. 6, 2023”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,192, Response filed Feb. 9, 2023 to Non Final Office Action mailed Nov. 30, 2022”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowability mailed Mar. 1, 2023”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Restriction Requirement mailed Mar. 2, 2023”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,192, Notice of Allowance mailed Mar. 8, 2023”, 8 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Feb. 27, 2023 to Office Action mailed Oct. 18, 2022”, w English Claims, 8 pgs.
[cited by applicant]
“International Application Serial No. PCT US2022 050087, International Search Report mailed Mar. 1, 2023”, 3 pgs.
[cited by applicant]
“International Application Serial No. PCT US2022 050087, Written Opinion mailed Mar. 1, 2023”, 4 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Decision of Rejection mailed Mar. 14, 2023”, w English translation, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Jan. 25, 2024 to Final Office Action mailed Nov. 1, 2023”, 13 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Response filed Jan. 30, 2024 to Notification of Reasons for Rejection mailed Oct. 31, 2023”, w English Claims, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Notice of Allowance mailed Feb. 14, 2024”, 8 pgs.
[cited by applicant]
“European Application Serial No. 23183741.0, Response filed Feb. 19, 2024 to Extended European Search Report mailed Jul. 21, 2023”, 12 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Response filed Feb. 27, 2024 to Notification of Reasons for Refusal mailed Nov. 11, 2023”, w english claims, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 18/144,368, Non Final Office Action mailed Apr. 12, 2024”, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed May 6, 2024 to Office Action mailed Dec. 22, 2023”, w current English claims, 15 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Examiners Decision of Final Refusal mailed May 14, 2024”, W English Translation, 4 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Rejection mailed May 14, 2024”, W English Translation, 25 pgs.
[cited by applicant]
“Recording of clinical analysis research association”, No. 5, [Online] Retrieved from the internet:http: www.jrsca.jp contents records contents Pdf 5-PDF?, (Feb. 2005), 3 pgs.
[cited by applicant]
Sugimoto, Ayurni, “Nervous Control of Glucose Metabolism in the Liver”, Lifestyle Research vol. 3, No. 1,, (2001), 138-141.
[cited by applicant]
“U.S. Appl. No. 17/329,842, Restriction Requirement mailed Oct. 17, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Final Office Action mailed Nov. 1, 2023”, 16 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Notification of Reasons for Rejection mailed Oct. 31, 2023”, W English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Nov. 11, 2023”, w English Translation, 10 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Dec. 22, 2023”, w English Translation, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Advisory Action mailed Apr. 30, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed Feb. 25, 2019”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed May 9, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Sep. 21, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Oct. 20, 2017”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Preliminary Amendment filed Jul. 28, 2015”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Jan. 17, 2018 to Non Final Office Action mailed Oct. 20, 2017”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Apr. 16, 2019 to Final Office Action mailed Feb. 25, 2019”, 18 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 7, 2018 to Final Office Action mailed May 9, 2018”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 25, 2017 to Restriction Requirement mailed Jul. 14, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Oct. 8, 2018 to Non Final Office Action mailed Sep. 21, 2018”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Restriction Requirement mailed Jul. 14, 2017”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Advisory Action mailed Jul. 30, 2019”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Corrected Notice of Allowability mailed Nov. 20, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed May 3, 2019”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed Aug. 16, 2018”, 26 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Feb. 15, 2018”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Nov. 30, 2018”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Notice of Allowance mailed Oct. 1, 2019”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Preliminary Amendment filed Apr. 20, 2016”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Mar. 20, 2019 to Non Final Office Action mailed Nov. 30, 2018”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jun. 14, 2018 to Non Final Office Action mailed Feb. 15, 2018”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jul. 1, 2019 to Final Office Action mailed May 3, 2019”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Oct. 26, 2018 to Final Office Action mailed Aug. 16, 2018”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Dec. 27, 2017 to Restriction Requirement mailed Oct. 31, 2017”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Restriction Requirement mailed Oct. 31, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Examiner Interview Summary mailed Jun. 4, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Final Office Action mailed Jan. 15, 2019”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed May 18, 2018”, 21 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed Sep. 14, 2018”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Notice of Allowance mailed Mar. 27, 2019”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Preliminary Amendment filed Apr. 26, 2017”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Mar. 14, 2019 to Final Office Action mailed Jan. 15, 2019”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Dec. 10, 2018 to Non Final Office Action mailed Sep. 14, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/156,163, Non Final Office Action mailed Apr. 2, 2020”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/156,163, Notice of Allowance mailed Jul. 22, 2020”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 16/156,163, Response filed Jul. 1, 2020 to Non Final Office Action mailed Apr. 2, 2020”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Preliminary Amendment filed Jul. 9, 2019”, 3 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Jan. 17, 2018”, (English Translation), 8 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Feb. 19, 2019”, W/ English Translation, 6 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed May 19, 2017”, W/ English Translation, 18 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Dec. 27, 2019”, w/ English translation, 12 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Apr. 2, 2018 to Office Action mailed Jan. 17, 2018”, w/ English claims, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Aug. 23, 2019 to Office Action mailed Feb. 19, 2019”, w/English Claims, 14 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Oct. 9, 2017 to Office Action mailed May 19, 2017”, w/ English Claims, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed 11-27-8 to Office Action mailed”, w/English Claims, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Jul. 2, 2020”, w/English translation, 14 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Sep. 3, 2019”, W/English Translation, 17 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Mar. 18, 2020 to Office Action mailed Sep. 3, 2019”, w/English Claims, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Voluntary Amendment mailed Feb. 22, 2018”, w/English Claims, 21 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 7 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Jun. 1, 2018”, 9 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Extended European Search Report mailed Jun. 6, 2016”, 6 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Office Action mailed Jun. 12, 2015”, 3 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Jul. 20, 2020 to Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 13 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Oct. 19, 2015 to Office Action mailed Jun. 12, 2015”, 13 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Dec. 1, 2016 to Extended European Search Report mailed Jun. 6, 2016”, 20 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 8 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Extended European Search Report mailed May 30, 2018”, 15 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Reponse filed Nov. 12, 2018 to Extended European Search Report mailed May 30, 2018”, 17 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Preliminary Report on Patentability mailed May 11, 2017”, 9 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Search Report mailed Jan. 21, 2016”, 2 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2015/058296, Written Opinion mailed Jan. 21, 2016”, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Jul. 4, 2017”, w/English Translation, 12 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Dec. 29, 2017”, With English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Mar. 16, 2018 to Office Action mailed Dec. 29, 2017”, w/ English Claims, 11 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Oct. 4, 2017 to Office Action mailed Jul. 4, 2017”, w/ English Claims, 19 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/ English Translation, 13 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Office Action mailed Jun. 23, 2020”, w/ English translation, 14 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Mar. 6, 2020 to Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/English Claims, 14 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Examiners Decision of Final Refusal mailed Apr. 7, 2020”, w/ English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jul. 2, 2019”, W/ English Translation, 16 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Oct. 1, 2019 to Notification of Reasons for Refusal mailed Jul. 2, 2019”, w/English Claims, 10 pgs.
[cited by applicant]
Krum, H., et aI., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.”, Lancet, 373(9671), (2009), 2375-1281.
[cited by applicant]
U.S. Appl. No. 17/719,032, filed Apr. 12, 2022, Chemical Ablation and Method of Treatment for Various Diseases.
[cited by applicant]
U.S. Appl. No. 17/329,765, filed May 25, 2021, Method of Treatment for Various Diseases.
[cited by applicant]
U.S. Appl. No. 17/329,795, filed May 25, 2021, Method of Treatment for Various Diseases.
[cited by applicant]
U.S. Appl. No. 17/329,823, filed May 25, 2021, Method of Treatment for Various Diseases.
[cited by applicant]
U.S. Appl. No. 17/329,842, filed May 25, 2021, Method of Treatment for Various Diseases.
[cited by applicant]
U.S. Appl. No. 14/438,411, filed Apr. 24, 2015, Chemical Ablation Formulations and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/419,587, filed May 22, 2019, Chemical Ablation Formulations and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/563,192, filed Sep. 6, 2019, Chemical Ablation Formulations and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 15/521,973 U.S. Pat. No. 10,286,191, filed Apr. 26, 2017, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/156,163 U.S. Pat. No. 10,758,713, filed Oct. 10, 2018, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/563,213, filed Sep. 6, 2019, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/986,717, filed Aug. 6, 2020, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 15/133,976 U.S. Pat. No. 10,537,375, filed Apr. 20, 2016, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/563,235, filed Sep. 6, 2019, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
U.S. Appl. No. 16/690,992, filed Nov. 21, 2019, Chemical Ablation and Methods of Treatments for Various Diseases.
[cited by applicant]
“Japanese Application Serial No. 202080044525.9, Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w English Translation, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed Jul. 26, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Aug. 11, 2022 to Non Final Office Action mailed May 12, 2022”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Aug. 26, 2022”, 7 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Response filed Sep. 2, 2022 to Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 116 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Non Final Office Action mailed Sep. 15, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Feb. 11, 2022”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Final Office Action mailed Feb. 24, 2022”, 18 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Mar. 9, 2022 to Final Office Action mailed Feb. 24, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Apr. 5, 2022”, 23 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Notice of Allowance mailed Apr. 11, 2022”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Corrected Notice of Allowability mailed Apr. 27, 2022”, 5 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-134047, Response filed Mar. 28, 2022 to Notification of Reasons for Refusal mailed Sep. 28, 2021”, w out English claims, Claims not amended in filed response, 21 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w out English claims, Claims not amended in response filed, 5 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w o English Claims, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed May 12, 2022”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Apr. 18, 2023 to Non Final Office Action mailed Feb. 6, 2023”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Apr. 19, 2023 to Restriction Requirement mailed Mar. 2, 2023”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed May 15, 2023”, 26 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Non Final Office Action mailed May 31, 2023”, 13 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Voluntary Amendment filed Jun. 19, 2023”, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Jun. 28, 2023 to Decision of Rejection mailed Mar. 14, 2023”, w English Claims, 13 pgs.
[cited by applicant]
Tian, Juanhua, “Rectifying disorder of extracellularmatrix to suppress urethral stricture by protein nanofilm-controlled drug delivery from urinary catheter”, nature communications, (5 17 2023), 17 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Non Final Office Action mailed Oct. 5, 2021”, 15 pgs.
[cited by applicant]
“Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma”, A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial Am J Respir Crit Care Med vol. 181., (2010), 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Nov. 4, 2021 to Non Final Office Action mailed Oct. 5, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Nov. 16, 2021 to Non Final Office Action mailed Sep. 30, 2021”, 13 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Nov. 16, 2021 to Notification of Reasons for Refusal mailed Aug. 17, 2021”, w Engilsh Claims, 10 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w English Translation, 17 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w English Translation, 8 pgs.
[cited by applicant]
Dunican, Eleanor M, “Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction”, J Clin Invest. 2018;128(3), (2018), 14 pgs.
[cited by applicant]
Greer, M, “Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation”, American Journal of Transplantation 2014 14: 2400-2405, (2014), 2400-2405.
[cited by applicant]
Kim, K. C., “Airway goblet cell mucin: its structure and regulation of secretion”, Series Airway Mucus Eur Respir J 1997; 10:, (1997), pp. 2644-2649.
[cited by applicant]
Krmisky, William, “Thermal ablation for asthma: current status and technique”, J Thorac Dis 2017;9(Suppl 2):S104-S109, (2017), 6 pgs.
[cited by applicant]
Menzella, Francesco, “Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights”, Journal of Asthma and Allergy 2020:13, (2020), 13 pgs.
[cited by applicant]
Peters, Michael C, “Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency”, Am J Respir Crit Care Med vol. 202, Iss 7, (2020), 10 pgs.
[cited by applicant]
Sakata, Kenneth K, “Paclitaxel-coated balloon dilation for central airway obstruction”, Respiratory Medicine Case Reports 24, (2018), 129-132.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Sep. 28, 2022 to Office Action mailed May 20, 2022”, w English Claims, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Oct. 26, 2022 to Final Office Action mailed Jul. 26, 2022”, 12 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Invitation pursuant to Article 94(3) and Rule 71(1) EPC mailed Oct. 11, 2022”, 4 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed Oct. 18, 2022”, w English translation, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Office Action mailed Nov. 8, 2022”, w English Translation, 45 pgs.
[cited by applicant]
“Japanese Application Serial No. 202080044525.9, Response filed Nov. 7, 2022 to Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w English Claims, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563, 192, Non Final Office Action mailed Nov. 30, 2022”, 21 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Response filed Dec. 13, 2022 to Non Final Office Action mailed Sep. 15, 2022”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2022/050087, International Preliminary Report on Patentability mailed May 30, 2024”, 6 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Jun. 4, 2024”, w/ English translation, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 18/144,368, Response filed Jul. 2, 2024 to Non Final Office Action mailed Apr. 12, 2024”, 11 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Jul. 10, 2024”, w English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Aug. 13, 2024 to Notification of Reasons for Rejection mailed May 14, 2024”, W English Claims, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 18/144,368, Notice of Allowance mailed Aug. 22, 2024”, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Response filed Sep. 3, 2024 to Notification of Reasons for Refusal mailed Jun. 4, 2024”, w English Claims, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed Sep. 10, 2024 to Office Action mailed Jul. 10, 2024”, w current English claims, 19 pgs.
[cited by applicant]